Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on <i>nab</i>-paclitaxel plus gemcitabine versus FOLFIRINOX

Abstract

Patients treated with nab-P + G (vs FOLFIRINOX) had similar treatment duration but lower costs of outpatient prescriptions, treatment administration and supportive care. Lower supportive care costs in the nab-P + G cohort were mainly driven by lower utilization of pegfilgrastim and anti-emetics.